Printer Friendly

KENNETH WOOLCOTT PROMOTED TO GENERAL COUNSEL AT IDEC PHARMACEUTICALS

KENNETH WOOLCOTT PROMOTED TO GENERAL COUNSEL AT IDEC PHARMACEUTICALS
 LA JOLLA and MOUNTAIN VIEW, Calif., April 1 /PRNewswire/ -- IDEC Pharmaceuticals Corp. (NASDAQ: IDPH) today announced that Kenneth J. Woolcott has been promoted to the position of general counsel. He was formerly deputy general counsel of the company.
 "Ken has demonstrated strength in the area of patents and intellectual property," said William H. Rastetter, Ph.D., IDEC's president and chief executive officer, "and he has grown into other areas of the law. He has contributed significantly in licensing and corporate development matters and has assumed increasing responsibility for the company's day-to-day legal affairs."
 Woolcott, 33, joined IDEC in early 1989 as intellectual property counsel, became intellectual property and licensing counsel in 1990 and was promoted to deputy general counsel in 1991. Prior experience in the biotechnology industry included responsibilities as patent counsel and later associate counsel of Hybritech Inc. Prior to joining IDEC, he was an associate at the Seattle law firm of Christensen, O'Connor, Johnson & Kindness. Woolcott will continue to report to Clifford Orent, IDEC's senior vice president and chief operating officer, who had also served as the company's general counsel until Woolcott's promotion.
 "Ken's promotion to general counsel at this time is consistent with his and the company's expectations when Ken joined IDEC," said Orent. "During his years with the company, Ken has continued to develop his knowledge of business, science and law, and has worked diligently on the company's behalf. His latest promotion is in recognition of the expanded role Ken has assumed within the company and is well deserved."
 Woolcott holds his juris doctor from George Washington University. He conducted graduate work in biochemical engineering at the University of Maryland and earned a bachelor of science in biochemistry from Pacific Lutheran University.
 IDEC Pharmaceuticals is a leader in the development of immunologically active monoclonal antibodies for therapeutic applications. Company products are designed to act through immune system mechanisms and may offer significant therapeutic advantages, such as specificity of action and duration of therapeutic effect, not available through the use of existing therapies. Current efforts are focused on the treatment of immune system cancers (lymphomas and leukemias), malignant melanoma, HIV infection and autoimmune disorders. Five products are in human clinical studies. The company's headquarters is located at 11099 North Torrey Pines Road, La Jolla, CA 92037. Phone: 619-458-0600.
 -0- 4/1/92
 /CONTACT: Clifford Orent, senior VP and COO of IDEC Pharmaceuticals, 415-940-1200/
 (IDPH) CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU: PER


DM-KJ -- SD005 -- 3987 04/01/92 15:28 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 1, 1992
Words:425
Previous Article:COLTEC INDUSTRIES COMPLETES RECAPITALIZATION
Next Article:UNITED TECHNOLOGIES AUTOMOTIVE TO KEEP PLYMOUTH, IND., PLANT OPEN
Topics:


Related Articles
IDEC PHARMACEUTICALS PROMOTES PHILLIP SCHNEIDER TO VICE PRESIDENT, FINANCE AND ADMINISTRATION
DAVID ROBINSON JOINS BOARD OF DIRECTORS OF IDEC PHARMACEUTICALS
NABIL HANNA PROMOTED TO SENIOR VICE PRESIDENT, RESEARCH AND PRECLINCIAL DEVELOPMENT AT IDEC PHARMACEUTICALS
WILLIAM ROHN JOINS IDEC PHARMACEUTICALS AS SENIOR VICE PRESIDENT, COMMERCIAL AND CORPORATE DEVELOPMENT
KENNETH WOOLCOTT PROMOTED TO VICE PRESIDENT, GENERAL COUNSEL & LICENSING EXECUTIVE OF IDEC PHARMACEUTICALS
CEPHALON APPOINTS SENIOR DIRECTOR AND PATENT COUNSEL
IDEC PHARMACEUTICALS APPOINTS PHILLIP SCHNEIDER CHIEF FINANCIAL OFFICER
IDEC PHARMACEUTICALS PROMOTES ANTONIO J. GRILLO-LOPEZ TO SENIOR VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
JOHN GEIGERT JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, QUALITY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters